|Bid||4.11 x 800|
|Ask||4.15 x 4000|
|Day's Range||4.1100 - 4.1800|
|52 Week Range||2.1300 - 5.8000|
|Beta (3Y Monthly)||-0.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
XBiotech Inc. (XBIT) today announced a successful GMP (Good Manufacturing Practices) audit by Eurofins Amatsigroup. The audit was conducted in connection with XBiotech’s distribution in Europe of its US-manufactured biological drug product. XBiotech manufactures bermekimab at its campus facility in Austin, Texas and regularly ships the drug to clinics in various countries in the European Union and the United Kingdom.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
XBiotech Inc. (XBIT) today provided an update on recent company developments in its third quarter Form 10-Q filing with the SEC. The Company reports that it continues to make important progress in its clinical and pre-clinical programs in addition to other corporate initiatives. In April 2018, XBiotech announced the launch of a Phase 2, open label clinical trial to evaluate the Company’s True Human™ monoclonal antibody, bermekimab, in patients with moderate to severe Atopic Dermatitis (AD).
XBiotech Inc. (XBIT) announced today that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis (AD). XBiotech has now completed and exceeded enrollment in the final cohort of patients who are receiving 400mg weekly doses of bermekimab over an 8 week treatment period. XBiotech recently announced it completed the first cohort of patients in the study who received a low dose of bermekimab (200mg/weekly) over a 4 week treatment regimen.
XBiotech Inc. (XBIT) announced today that the European Patent Office has granted XBiotech a patent (Patent Number EP2694107) that covers the use of bermekimab as a treatment for inflammatory skin diseases. The patent includes data from studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α) can reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab (an anti- IL-1α antibody), including ongoing studies in hidradenitis suppurativa and atopic dermatitis.
AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). XBiotech plans to accept a limited number of additional patients in Europe prior to study completion. John Simard, Chairman & CEO of XBiotech, commented, “We are very pleased by the enrollment rate we have seen in this study.
XBiotech Inc. (XBIT) announced today the addition of Alice Gottlieb, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of biological therapies to treat skin diseases. Dr. Gottlieb has played key roles in the clinical evaluation of therapies such as etanercept, infliximab, ustekinumab and secukinumab. Dr. Gottlieb will work to help guide the clinical development of bermekimab, the Company’s candidate antibody therapy for skin diseases.
XBiotech Inc. (XBIT) announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis (AD). In the first phase of the study, 9 patients received a low dose (200mg/weekly) over a short course of treatment (4 weeks). The SCORAD, a clinical tool for assessing extent and intensity of atopic dermatitis, showed a mean improvement of 25% for the cohort after 4 weeks.
XBiotech Inc. (XBIT) is pleased to announce the appointment of Peter Libby, MD to its Scientific Advisory Board (SAB). Dr. Libby will work with XBiotech to help further develop its clinical and research programs including studies evaluating bermekimab’s potential in improving patient outcomes by reducing risk of heart attack or strokes. Dr. Libby’s group recently published their discovery that a crucial mechanism behind heart attacks and stroke may involve inflammation that is targeted by the Company’s antibody, bermekimab.
AUSTIN, Texas, July 10, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating ...
XBiotech Inc. (XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating MABp1 in patients with moderate to severe Atopic Dermatitis (AD). The patient began treatment at Florida Academic Dermatology Center under the care of the Study`s Chair, Dr. Francisco Kerdel.
XBiotech to Launch Two Phase 2 Clinical Studies to Study Subcutaneous Administration of MABp1 for Treatment of Hidradenitis Suppurativa and Atopic Dermatitis AUSTIN, Texas, April 16, 2018 (GLOBE NEWSWIRE) ...
Agreement Centers on XBiotech`s Proprietary Manufacturing Technology to Advance Anti-NY-ESO-1 Antibody 12D7 AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- XBiotech USA, Inc. (NASDAQ:XBIT) announced ...
LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on XBiotech Inc. (NASDAQ: XBIT ). If you want access to this report all you need to do is sign ...
Data Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) Provide Results that Corroborate HiSCR findings with iHS4 Scoring as a Measure of Efficacy AUSTIN, Texas, ...
Report Documents 514G3`s Ability to Protect Mice Against Deadly S. aureus Bacteremia Infections AUSTIN, Texas, Jan. 25, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today the publication ...